Structure-guided development of a potent human B<sup>0</sup>AT1 inhibitor effective in a mouse model of phenylketonuria.
AT1 and establish a framework for the rational optimization of inhibitors targeting conformationally dynamic allosteric sites in SLC6-family transporters.
Authors
- Hiromi Hisano
- Wataru Sasaki (ORCID: https://orcid.org/0000-0003-1418-6566)
- N. Fujikawa
- Tsukasa Kusakizako (ORCID: https://orcid.org/0000-0002-6186-6647)
- Osamu Nureki (ORCID: https://orcid.org/0000-0003-1813-7008)
- Tomoya Akashi (ORCID: https://orcid.org/0000-0002-2802-080X)
- Ikuko Miyaguchi (ORCID: https://orcid.org/0000-0003-0021-7296)
- Taichi Kumanomidou
- Yosuke Inui
- Hidenori Todoroki
- Takuya Imazu
- Masahiro Hiraizumi (ORCID: https://orcid.org/0000-0002-4340-2937)
- Tomohiro Nishizawa (ORCID: https://orcid.org/0000-0001-7463-8398)
- Hidetsugu Asada (ORCID: https://orcid.org/0000-0001-6255-4728)
- Tsuyoshi Takahashi (ORCID: https://orcid.org/0000-0001-6862-4352)
- So Iwata (ORCID: https://orcid.org/0000-0003-1735-2937)
- K Yamada
Institutions
- Mitsubishi Group (Japan) (JP)
- Kyoto University (JP)
- Mitsubishi Chemical Group Science and Technology Research Center (Japan) (JP)
- Tanabe Research Laboratories (US)
- The University of Tokyo (JP)
- Yokohama City University (JP)
Publication Details
- Journal
- PubMed
- Published
- 2026-06-25
- DOI
- https://doi.org/10.1038/s42003-026-10535-y
- Primary Topic
- Metabolism and Genetic Disorders
- Type
- article
- Field-Weighted Citation Impact
- 0.00